Drugs / FAZPILODEMAB
FAZPILODEMAB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03060538 | Mar 2017 → Dec 2019 | NAFLD1, type 2 diabetes mellitus | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02593331 | Oct 2015 → Mar 2017 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04171765 | Sep 2020 → Jan 2023 | metabolic dysfunction-associated steatohepatitis | Genentech, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAZPILODEMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297909 ↗ |
| Known as | BFKB8488A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04171765 ↗ |
| Known as | RG-7992 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297909 ↗ |
| Known as | RO-7040551 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297909 ↗ |
| Action | Activate | “Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A” PMID 35993161 ↗ Sep 2022 |
| Modality | Monoclonal antibody | — CHEMBL4297909 ↗ |
| Route | Subcutaneous | “administered SC” NCT02593331 ↗ |